Sprycel And Vidaza Generics Among Five First-Times For Sawai
Sawai ‘Operating At Night And On Holidays’ To Meet Supply Shortages
Executive Summary
Fresh from announcing a major deal that will see it take over a network of facilities, Japanese player Sawai says its aim is to “further increase production by strengthening the personnel structure.”
You may also be interested in...
Sawai Focuses On New Products, Supply To 'Retain Trust' of Japan Generic Industry
Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.
Sawai Focuses On New Products, Supply To 'Retain Trust' of Japan Generic Industry
Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.
What’s Next? Five Things To Look Out For In March
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.